

Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum- based chemotherapy (terminated appraisal)

Technology appraisal guidance

Published: 29 May 2024

www.nice.org.uk/guidance/ta976

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer in adults who need systemic treatment after platinum-based chemotherapy with or without immunotherapy. This is because Daiichi Sankyo has confirmed that it does not intend to make an evidence submission for the appraisal. Daiichi Sankyo considers that the technology is unlikely to be a cost-effective use of NHS resources under the current NICE methods.

Information

If NHS organisations wish to consider trastuzumab deruxtecan for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-6137-5